05 enero 2021

PharmaMar Lidera las Subidas del Ibex en 2021 a Semanas de Que Presente su Protocolo Para la Autorización de Inicio del Ensayo de Fase III del Aplidin . Está Previsto Que Remita Dicho Protocolo a la AEMPS , Antes de Que Finalice el Mes de Enero .

 


COVID19 . Bill Gates Que Parece Ser el Que Maneja los Tempos Ha Vaticinado Que el Regreso de la Vida Normal Llegará Aproximadamente Durante la Próxima Primavera . Vacunas Puestas y Todos Contentos Como lo Están Ya en Wuhan .. Cuna del Virus .

 


OMS . El Uso de Ivermectina Implicaría una Reducción del 83 % de la Mortalidad por COVID19 Tanto en Pacientes Moderados Como en Graves . Esta Fue una de las Conclusiones Más Importantes de una Investigación Financiada Por la OMS , Que Llevó a Cabo un Meta-Análisis de los Resultados de 11 Ensayos Clínicos Realizados en Diferentes Países Que en Total Reunió a 1452 Voluntarios

 


COVID19 // Ivermectina , el Tratamiento Que Cuesta Alrededor de $1 Por Toma , Podría Reducir las Tasas de Mortalidad Hasta en un 80% ... Según una Presentación Filtrada por Científicos de la Universidad de Liverpool.

 

  • Ivermectin Costs As Little As $1 Per Course, Could Cut Mortality Rates By As Much As 80% .

LONDON: Early-stage trials indicate that a cheap and readily available drug has the potential to make “transformative” changes to COVID-19 mortality rates, according to a leaked presentation by Liverpool University scientists.

Data revealed in the presentation suggested that the drug Ivermectin — normally used to treat lice — could cut deaths in hospitals by as much as 80 percent.

In 11 trials involving more than 1,000 patients, those who received the drug appeared to clear themselves of the virus in about half the usual time.

Trials of another 5,000 patients have yet to report their results, but Dr. Andrew Hill, the researcher at Liverpool University who gave the leaked presentation, said they are expected soon.

He emphasized that his data looked only at the so-called “gold-standard” randomized controlled trials, in which patients were randomly assigned the drug or a placebo.

“The combined data may be large enough to get to World Health Organization recommendations for treatment being used worldwide,” Hill said.

“If we see these same trends consistently across more studies, then this really is going to be a transformative treatment.”

He said the anti-parasitic drug could be a particularly important weapon against COVID-19 in the developing world because of its low cost. “It’s very attractive because it costs between $1 and $2 for a treatment course,” Hill added.

Despite the early positive signs, however, other researchers have urged caution over pre-emptively heralding a wonder treatment.

Other drugs such as hydroxychloroquine have previously been touted as major breakthroughs in COVID-19 treatment, only to underperform in large-scale trials.

Oxford University Prof. Peter Horby said he is worried that the mortality data involved too few cases, and that many of the trials analyzed had not been peer reviewed. The new data, he added, is “interesting, perhaps encouraging, but not yet convincing.” 

FDA Ha Aprobado Una Combinación Triple de Xpovio ( Selinexor ) Más Velcade ( Bortezomib ) y Dexametasona en Dosis Bajas Para el Tratamiento de Personas con Mieloma Múltiple Que Recibieron al Menos Una Línea de Terapia .

 


Carrimycin . COVID-19 Treatment Is The First Synthetic Biological Drug To Receive FDA Approval For Phase 3 Trials .

 


El Mercado Espera Que Pharmamar Presente en Breve a la Agencia Española de Medicamentos el Protocolo de Fase Tres .